AGILE THERAPEUTICS INC (AGRX) Stock Price, Quote, News and Overview
NASDAQ:AGRX - Nasdaq - US00847L3087 - Common Stock - Currency: USD
AGRX Quote, Performance and Key Statistics
0.6022
+0.06 (+10.11%)
The current stock price of AGRX is 0.6022 USD. In the past month the price decreased by -25.49%. In the past year, price decreased by -94.62%.
AGRX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.48 | 831.66B | ||
| JNJ | JOHNSON & JOHNSON | 15.46 | 374.37B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 18.15 | 277.97B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.19 | 222.45B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.85 | 216.81B | ||
| MRK | MERCK & CO. INC. | 10.68 | 209.34B | ||
| PFE | PFIZER INC | 7.41 | 130.73B | ||
| SNY | SANOFI-ADR | 13.7 | 129.16B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.6 | 98.60B | ||
| GSK | GSK PLC-SPON ADR | 8.75 | 77.12B | ||
| ZTS | ZOETIS INC | 25.94 | 68.50B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 32.96 | 47.71B |
Related stock screener links
About AGRX
Company Profile
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patches. The company is headquartered in Princeton, New Jersey and currently employs 22 full-time employees. The company went IPO on 2014-05-22. The Company’s sole approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch. Twirla is a method of contraception for use in women of reproductive potential for whom a combined hormonal contraceptive is appropriate. Twirla is a prescription combined hormonal contraceptive patch, which contains the active ingredients ethinyl estradiol (EE), which is a synthetic estrogen and levonorgestrel (LNG), which is a type of progestin. Twirla delivers 30 micrograms of EE per day, a dose of EE consistent with the dose delivered by many commonly prescribed oral contraceptives. The firm commercializes Twirla in the United States. Twirla leverages the Company’s transdermal patch technology called Skinfusion. Skinfusion is designed to allow drug delivery through the skin while optimizing patch adhesion and patient comfort and wearability.
Company Info
AGILE THERAPEUTICS INC
500 College Road East, Suite 310
Princeton NEW JERSEY 08540 US
CEO: Alfred Altomari
Employees: 22
Company Website: https://www.agiletherapeutics.com/
Phone: 16096831880
AGILE THERAPEUTICS INC / AGRX FAQ
What is the stock price of AGILE THERAPEUTICS INC today?
The current stock price of AGRX is 0.6022 USD. The price increased by 10.11% in the last trading session.
What is the ticker symbol for AGILE THERAPEUTICS INC stock?
The exchange symbol of AGILE THERAPEUTICS INC is AGRX and it is listed on the Nasdaq exchange.
On which exchange is AGRX stock listed?
AGRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AGILE THERAPEUTICS INC stock?
7 analysts have analysed AGRX and the average price target is 5.1 USD. This implies a price increase of 746.89% is expected in the next year compared to the current price of 0.6022. Check the AGILE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AGILE THERAPEUTICS INC worth?
AGILE THERAPEUTICS INC (AGRX) has a market capitalization of 1.51M USD. This makes AGRX a Nano Cap stock.
How many employees does AGILE THERAPEUTICS INC have?
AGILE THERAPEUTICS INC (AGRX) currently has 22 employees.
What are the support and resistance levels for AGILE THERAPEUTICS INC (AGRX) stock?
AGILE THERAPEUTICS INC (AGRX) has a resistance level at 0.75. Check the full technical report for a detailed analysis of AGRX support and resistance levels.
Is AGILE THERAPEUTICS INC (AGRX) expected to grow?
The Revenue of AGILE THERAPEUTICS INC (AGRX) is expected to grow by 101% in the next year. Check the estimates tab for more information on the AGRX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AGILE THERAPEUTICS INC (AGRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AGRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AGRX, evaluating the profitability, health, valuation and growth aspects
- AGILE THERAPEUTICS INC (AGRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AGILE THERAPEUTICS INC (AGRX) Sales and EPS estimates to see what analysts future expectations are.
- AGILE THERAPEUTICS INC (AGRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AGILE THERAPEUTICS INC (AGRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- AGILE THERAPEUTICS INC (AGRX) Stock Chart to make your own analysis
- AGILE THERAPEUTICS INC (AGRX) Latest news and press-releases to stay up to date.
Does AGILE THERAPEUTICS INC (AGRX) stock pay dividends?
AGRX does not pay a dividend.
When does AGILE THERAPEUTICS INC (AGRX) report earnings?
AGILE THERAPEUTICS INC (AGRX) will report earnings on 2024-05-09, before the market open.
What is the Price/Earnings (PE) ratio of AGILE THERAPEUTICS INC (AGRX)?
AGILE THERAPEUTICS INC (AGRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-13.33).
AGRX Technical Analysis
AGRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AGRX. AGRX may be in some trouble as it scores bad on both profitability and health.
AGRX Financial Highlights
Over the last trailing twelve months AGRX reported a non-GAAP Earnings per Share(EPS) of -13.33. The EPS increased by 97.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 41.26% | ||
| ROA | 75.6% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
AGRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to AGRX. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 93.92% and a revenue growth 101% for AGRX